CSPC Pharmaceutical Group Limited (1093.HK)
1093.HK Stock Price Chart
Explore CSPC Pharmaceutical Group Limited interactive price chart. Choose custom timeframes to analyze 1093.HK price movements and trends.
1093.HK Company Profile
Discover essential business fundamentals and corporate details for CSPC Pharmaceutical Group Limited (1093.HK) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Drug Manufacturers - General
IPO Date
21 Jun 1994
Employees
21.40K
Website
https://www.cspc.com.hkCEO
Cuilong Zhang
Description
CSPC Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical products in the People's Republic of China, other Asian regions, the Americas, Europe, and internationally. The company operates through Finished Drugs, Bulk Products, and Functional Food and Others segments. It provides NBP soft capsules and injections for acute ischemic stroke; Oulaining capsules and injections to treat mild to moderate memory and mental impairment; Enxi to treat adult idiopathic Parkinson's disease; Duomeisu for lymphoma, multiple myeloma, ovarian and breast cancers, and other malignant tumors; Jinyouli to prevent leucopenia and infection induced by chemotherapy; and Keaili for breast cancer. The company also offers Shuluoke, Nuomoling, Weihong, and Xinweihong for various infections; Xuanning for hypertension; Encun to prevent atherosclerotic thrombosis events; Qixiao to treat upper respiratory tract infection; Linmeixin and Shuanglexin for diabetes; Gubang and Gubangjia to treat osteoporosis in postmenopausal women; and Gaoshunsong for arthritis, osteoarthritis, ankylosing spondylitis, frozen shoulder, bursuitis, tenosynovitis, acute gout, dysmenorrhea, toothache and postoperative pain, low back pain, sprain, strain, and other soft tissue injuries. In addition, it provides Debixin for various ulcer; Qimaite for acute and chronic pains; antibiotics, vitamin C, and caffeine APIs; functional food and glucose products; and healthcare services. The company was formerly known as China Pharmaceutical Group Limited and changed its name to CSPC Pharmaceutical Group Limited in March 2013. CSPC Pharmaceutical Group Limited was incorporated in 1992 and is headquartered in Shijiazhuang, the People's Republic of China.
1093.HK Financial Timeline
Browse a chronological timeline of CSPC Pharmaceutical Group Limited corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 27 May 2026
Dividend declared on 17 Oct 2025
A dividend of $0.14 per share was announced, adjusted to $0.14. The dividend will be paid on 18 Nov 2025.
Earnings released on 22 Aug 2025
EPS came in at $0.24 , while revenue for the quarter reached $14.54B , beating expectations by +75.22%.
Dividend declared on 4 Jun 2025
A dividend of $0.10 per share was announced, adjusted to $0.10. The dividend was paid on 18 Jul 2025.
Earnings released on 29 May 2025
EPS came in at $0.13 surpassing the estimated $0.12 by +8.33%, while revenue for the quarter reached $14.59B , beating expectations by +79.37%.
Earnings released on 15 Nov 2024
EPS came in at $0.27 surpassing the estimated $0.11 by +148.64%, while revenue for the quarter reached $16.28B , beating expectations by +110.06%.
Dividend declared on 31 Oct 2024
A dividend of $0.16 per share was announced, adjusted to $0.16. The dividend was paid on 20 Nov 2024.
Dividend declared on 31 May 2024
A dividend of $0.14 per share was announced, adjusted to $0.14. The dividend was paid on 26 Jun 2024.
Earnings released on 27 May 2024
EPS came in at $0.14 surpassing the estimated $0.12 by +16.67%, while revenue for the quarter reached $15.04B , beating expectations by +83.61%.
Earnings released on 30 Nov 2023
EPS came in at $0.13 matching the estimated $0.13, while revenue for the quarter reached $8.03B , missing expectations by -8.67%.
Dividend declared on 7 Sept 2023
A dividend of $0.14 per share was announced, adjusted to $0.14. The dividend was paid on 12 Oct 2023.
Dividend declared on 5 Jun 2023
A dividend of $0.11 per share was announced, adjusted to $0.11. The dividend was paid on 28 Jun 2023.
Earnings released on 25 May 2023
EPS came in at $0.13 matching the estimated $0.13, while revenue for the quarter reached $15.10B , beating expectations by +68.65%.
Earnings released on 23 Nov 2022
EPS came in at $0.13 surpassing the estimated $0.12 by +8.33%, while revenue for the quarter reached $16.09B , missing expectations by -12.14%.
Dividend declared on 8 Sept 2022
A dividend of $0.10 per share was announced, adjusted to $0.10. The dividend was paid on 11 Oct 2022.
Dividend declared on 31 May 2022
A dividend of $0.10 per share was announced, adjusted to $0.10. The dividend was paid on 22 Jun 2022.
Earnings released on 25 May 2022
EPS came in at $0.12 falling short of the estimated $0.16 by -25.00%, while revenue for the quarter reached $17.00B , missing expectations by -4.15%.
Earnings released on 18 Nov 2021
EPS came in at $0.11 matching the estimated $0.11, while revenue for the quarter reached $16.59B .
Dividend declared on 10 Sept 2021
A dividend of $0.08 per share was announced, adjusted to $0.08. The dividend was paid on 8 Oct 2021.
Earnings released on 24 May 2021
EPS came in at $0.12 surpassing the estimated $0.10 by +20.00%, while revenue for the quarter reached $14.13B , missing expectations by -17.98%.
Dividend declared on 24 May 2021
A dividend of $0.09 per share was announced, adjusted to $0.09. The dividend was paid on 11 Jun 2021.
Earnings released on 23 Nov 2020
EPS came in at $0.10 matching the estimated $0.10, while revenue for the quarter reached $13.89B .
Stock split effective on 15 Oct 2020
Shares were split 8 : 5 , changing the number of shares outstanding and the price per share accordingly.
Dividend declared on 10 Sept 2020
A dividend of $0.06 per share was announced, adjusted to $0.04. The dividend was paid on 9 Oct 2020.
1093.HK Stock Performance
Access detailed 1093.HK performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.